Inflammatory Bowel Disease (IBD) management, particularly with biologic therapies like infliximab, has long been challenged by issues such as antibody formation, variable drug clearance, and the high costs associated with frequent dosing. In many cases, biologics are introduced only in advanced disease stages, making it essential to find a balance between effective treatment and affordability.

At P.D. Hinduja Hospital & Medical Research Centre, Dr. Devendra Desai, a gastroenterologist, and Dr. Alpa Dherai, a biochemist specializing in therapeutic drug monitoring (TDM), are leveraging Baysient’s iDose platform to tackle these challenges head-on. In their recent video testimonial, they share powerful examples of how iDose is transforming their approach to infliximab therapy, offering a new level of precision that minimizes antibody formation and ensures therapeutic effectiveness over time.